2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
22
Neoplasms
20
Leukemia, Myeloid, Acute
10
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Lymphoma
7
Lung Neoplasms
7
Hematologic Neoplasms
6
Glioblastoma
6
Colorectal Neoplasms
6
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Leukemia
5
Fatigue
5
Stomach Neoplasms
4
Depression
4
Carcinoma, Non-Small-Cell Lung
4
Vulvar Neoplasms
3
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pain
3
Myelodysplastic Syndromes
3
Motor Activity
3
Melanoma
3
Carcinoma, Hepatocellular
3
Anxiety Disorders
3
Interventions
Doxorubicin
17
Echocardiography
14
Exercise
9
Cyclophosphamide
9
Trastuzumab
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
Palliative Care
×
Clear all
NCT04598646
2025-12-03
HIMALAYAS-P
University Health Network, Toronto
Phase NA
Completed
30 enrolled